PBE - ETF AI Analysis
Top Page
Invesco Dynamic Biotechnology & Genome ETF (PBE)
PBE, the Invesco Dynamic Biotechnology & Genome ETF, earns a solid overall rating thanks to several strong, well-established biotech leaders like Gilead Sciences, Vertex Pharmaceuticals, Regeneron, and Royalty Pharma, which bring robust financial performance, healthy pipelines, and positive earnings trends to the portfolio. These strengths are partly offset by weaker holdings such as Moderna and Novavax, where declining revenues, ongoing losses, and financial instability introduce more risk. The main risk factor is the fund’s concentrated exposure to the biotechnology and genome sector, which can make performance more volatile and sensitive to industry-specific setbacks.
PBE vs. SPDR S&P 500 ETF (SPY)
- AUM
- 445.63M
- Region
- North America
- Expense Ratio
- 0.59%
- Beta
- 0.66
- Issuer
- Invesco
- Inception Date
- Jun 23, 2005
- Dividend Yield
- 1.30%
- Asset Class
- Equity
- Index Tracked
- Dynamic Biotech & Genome Intellidex Index (AMEX)
PBE Summary
PBE is the Invesco Dynamic Biotechnology & Genome ETF, which follows the Dynamic Biotech & Genome Intellidex Index. It focuses on U.S. health care companies working in biotechnology and genetic research—areas like new medicines, gene-based treatments, and advanced lab tools. Well-known holdings include Moderna and Amgen, along with other biotech leaders. Someone might invest in PBE to seek long-term growth from medical and genetic breakthroughs and to get broad exposure to many biotech stocks in one fund. A key risk is that biotech shares can be very volatile, so the ETF’s price can move up and down sharply with the sector.
How much will it cost me?
This ETF has an expense ratio of 0.59%, which means you’ll pay about $5.90 per year for every $1,000 you invest. That’s higher than the average ETF because it’s a specialized, actively managed fund focused on the biotechnology and genome sector.
What would affect this ETF?
PBE could benefit if demand for new drugs and genetic testing grows, health care spending rises in the U.S., or if its major biotech holdings like Illumina, Biogen, and Amgen see successful product launches or favorable regulatory approvals. On the downside, the fund may be hurt by stricter drug regulations, setbacks in clinical trials, changes in U.S. health care policy, or rising interest rates that make investors less willing to back riskier, research-focused biotech companies.
PBE Top 10 Holdings
PBE is a pure-play U.S. biotech fund, and its story right now is all about innovative drug makers and genomic leaders. Illumina and Natera have been steadily rising, giving the ETF a lift as demand for genetic testing and sequencing picks up. Big pharma-style names like Biogen, Amgen, and Gilead are more like sturdy anchors—up, but not sprinting—helping smooth out volatility. Moderna, despite mixed fundamentals, has been surging lately and adds a more speculative edge. Overall, the fund is tightly concentrated in cutting-edge health care, with performance driven by a handful of key biotech innovators.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 ILMN | Illumina | 5.04% | $22.31M | $35.63B | 138.35% | 71Outperform |
 NTRA | Natera | 5.92% | $26.17M | $59.72B | 114.42% | 73Outperform |
 BIIB | Biogen | 5.52% | $24.43M | $37.49B | 69.52% | 74Outperform |
 GILD | Gilead Sciences | 5.52% | $24.40M | $211.64B | 44.11% | 78Outperform |
 RPRX | Royalty Pharma | 5.21% | $23.02M | $38.72B | 81.86% | 79Outperform |
 AMGN | Amgen | 5.07% | $22.41M | $251.94B | 59.59% | 77Outperform |
 REGN | Regeneron | 5.35% | $23.67M | $95.51B | 41.87% | 78Outperform |
 VRTX | Vertex Pharmaceuticals | 4.86% | $21.50M | $141.65B | 33.10% | 78Outperform |
 MRNA | Moderna | 3.66% | $16.19M | $88.52B | 687.92% | 59Neutral |
 HALO | Halozyme | 3.14% | $13.89M | $14.86B | 102.55% | 73Outperform |
PBE Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PBE, the sentiment is Positive. The current price of 102.50 is above the 20-day moving average (MA) of 98.09, above the 50-day MA of 96.98, and above the 200-day MA of 86.79, indicating a bullish trend. The MACD of 1.65 indicates Negative momentum. The RSI at 64.19 is Neutral, neither overbought nor oversold. The STOCH value of 89.93 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PBE.
PBE Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| PBE | $102.50 | $107.00(4.39% Upside) | $445.63M | 0.59% | 70Outperform |
 RSPH | $39.69 | $42.51(7.09% Upside) | $991.68M | 0.40% | 71Outperform |
 PJP | $130.54 | $159.85(22.45% Upside) | $575.09M | 0.58% | 70Neutral |
 XPH | $64.80 | $109.32(68.70% Upside) | $466.58M | 0.35% | 56Neutral |
 SBIO | $54.87 | $112.31(104.68% Upside) | $187.80M | 0.50% | 46Neutral |
 BBP | $104.18 | $152.63(46.51% Upside) | $136.83M | 0.34% | 60Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PBE | Invesco Dynamic Biotechnology & Genome ETF | 102.50 | 29.00 | 39.46% | |
| RSPH | Invesco S&P 500 Equal Weight Health Care ETF | 39.69 | 9.65 | 32.11% | |
| PJP | Invesco Dynamic Pharmaceuticals ETF | 130.54 | 34.57 | 36.02% | |
| XPH | SPDR S&P Pharmaceuticals ETF | 64.80 | 15.34 | 31.00% | |
| SBIO | ALPS Medical Breakthroughs ETF | 54.87 | 10.92 | 24.84% | |
| BBP | Virtus LifeSci Biotech Products ETF | 104.18 | 30.44 | 41.29% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.